Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rex Fang & Innovation Equity Premium Income ETF vs DENTSPLY SIRONA Inc — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $43.51 (market cap $746.48M), while DENTSPLY SIRONA Inc trades at $8.82 (market cap $1.73B). The key difference: DENTSPLY SIRONA Inc is far larger — about 2.3× Rex Fang & Innovation Equity Premium Income ETF's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Rex Fang & Innovation Equity Premium Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Rex Fang & Innovation Equity Premium Income ETF for 56 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| FEPI | XRAY | |
|---|---|---|
Market Cap | $746.48M | $1.73B |
Volume | 334,337 | 6,198,582 |
Sector | Income / Options Overlay | Health |
52-Week High | $49.54 | $14.68 |
52-Week Low | $37.98 | $8.52 |
Typical Hold Time | 56 Days | 72 Days |
Enterprise Value | — | $3.80B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FEPI (REX FANG & Innovation Equity Premium Income ETF) trades at $43.51, down 0.18% with a bullish technical signal from moving averages. The ETF employs a covered call strategy on concentrated AI and mega-cap tech holdings, generating high weekly distributions averaging $0.20-0.21. Recent articles highlight its 25% trailing yield but note capped upside potential and underperformance versus peers in total return during tech rallies.
The outlook balances high income generation against significant risk from tech concentration and volatility dependence. While the covered call strategy funds substantial dividends, it limits capital appreciation during market upswings. Key risks include drawdown vulnerability if tech stocks decline and competitive pressure from higher-performing income alternatives. Analyst sentiment remains cautious due to the trade-off between yield and total return potential.
DENTSPLY SIRONA (XRAY) trades at $8.83, down 3.4% with bearish technical signals. The stock faces fundamental challenges with negative net income margins (-14.99%) and declining revenue trends ($3.68B in 2025). Recent Q2 2026 earnings beat expectations but sales fell 4.1% amid ongoing turnaround efforts. The company maintains strong institutional interest despite hitting 52-week lows in September 2026.
XRAY presents a high-risk opportunity with Wall Street maintaining a cautious stance (37.5% buy rating). The consensus price target of $13.40 offers 52% upside potential, but investors face execution risks in the dental equipment turnaround, margin pressures, and competitive challenges. Near-term catalysts include management's presentation at the Baird Healthcare Conference in September 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
